

Brand Name: Ultomiris

Generic: ravulizumab

Type: monoclonal antibody

Year Accepted/Phase:

paroxysmal nocturnal hemoglobinuria (PNH) 2007

atypical hemolytic uremic syndrome (aHUS) 2011

Mechanism:

Ravulizumab is a monoclonal antibody that targets and inhibits the complement protein C5, which is part of the immune system. By inhibiting the complement cascade, ravulizumab helps to reduce hemolysis in PNH and prevent damage to organs in aHUS.

Chemical Structure: N/A

Indication:

Ultomiris is indicated for the treatment of PNH to reduce hemolysis, and for the treatment of aHUS to inhibit thrombotic microangiopathy (blood clot formation in small blood vessels).

Clinical trials:

Clinical Trials for PNH and aHUS

Purpose: Evaluate the efficacy and safety of ravulizumab in patients with PNH and aHUS.

Dates: Clinical trials for Ultomiris were conducted in the 2010s.

Results: These trials demonstrated that ravulizumab reduced hemolysis (destruction of red blood cells) in patients with PNH and improved renal function in patients with aHUS.

Impact: The positive results from these trials supported the approval of Ultomiris for the treatment of PNH and aHUS.